In conclusion, for the first time we report a large series of patients in which overexpression of GATA2 is a recurrent event associated with a poor outcome in AML. We also confirmed GATA2 overexpression at the protein level. GATA2 overexpression was significantly associated with FLT3-ITD mutations in patients with a NK, suggesting that these may represent cooperative events in AML. Our data indicate that GATA2 overexpression may be a useful molecular marker for predicting clinical outcome in AML. However, further studies will be required to elucidate the biological consequences of the overexpression of this transcription factor.
Acute myeloid leukemia (AML) is clinically and molecularly a heterogeneous disease. The less-characterized AML subgroup, accounting for about 50% of cases, is the one usually referred to as AML with normal karyotype (AML-NK), whose molecular characteristics still require to be fully determined. During the past decade, several mutations have been identified in association with AML-NK, and two of them were recognized by the 2008 World Health Organization (WHO) classification as defining provisional entities with characteristic biological and clinical features: AML with mutated nucleophosmin (NPM1) [1] [2] [3] and AML with mutated CCAAT/enhancer-binding protein alpha (CEBPA). 1 More recently, whole-genome and whole-exome sequencing technologies have been used to further unravel the genomic landscape of AML-NK. Novel mutations so far identified in AML-NK using these approaches include those involving the IDH1, IDH2 and DNMT3A genes, [4] [5] [6] and others are expected to be found in the future by sequencing additional AML-NK genomes.
The DNMT3A gene encodes the DNA methyltransferase 3A, an enzyme that catalyzes the process of de novo DNA methylation, that is, the addition of a methyl group to the cytosine residue of CpG dinucleotides. Mutations of DNMT3A have been reported in about 20% of adult de novo AML cases, 5, 6 mostly associated with normal karyotype. Presence of DNMT3A mutations seems to be associated with an adverse outcome. 5, 6 In the great majority of DNMT3A-mutated AML patients, both the normal and the mutated allele of DNMT3A are expressed. As many as 33 different DNMT3A mutations have been described so far in AML patients, mostly involving the methyltransferase domain of the protein. 5, 6 It has been suggested that DNMT3A mutations may induce epigenetic changes by affecting the DNA methyltransferase activity, 6 leading to the hypothesis that, besides genomic DNA alterations, epigenetic dysregulation may contribute to leukemogenesis. 7 Indeed, changes in DNA methylation or histone modification patterns have been demonstrated by epigenetic profiling in AML 8 and these alterations may be targeted by 'epigenetic' drugs.
The role of DNMT3A mutations in the pathogenesis of AML remains largely enigmatic, 9 and the availability of DNMT3A-mutated human cell lines could be a useful tool to address this issue by establishing model systems for functional analyses. In the attempt to identify human AML cell lines carrying DNMT3A mutations, we screened five well-established human AML cell lines (OCI-AML2, OCI-AML3, HL-60, KG1 and U937) that are commonly used for the study of the biological properties and response to drug of AML cells.
The five human AML cell lines were obtained from the German Collection of Microorganisms and Cell Cultures (Braunschweig, Lower Saxony, Germany). Genomic DNA extraction, PCR amplification and bidirectional Sanger sequencing of all coding exons of DNMT3A were done according to the standard procedures by Genewiz (South Plainfield, NJ, USA) using the primers listed in Table 1 . Analysis of the chromatograms was done with the help of Mutation Surveyor (Softgenetics, State College, PA, USA) using the DNMT3A RefSeqs NC_000002.11 (genomic locus; hg build 37.2), NM_175629.1 (the longest transcript) and NP_783328.1 (the longest protein isoform) as reference. Every sequence variant was checked against dbSNP (build 132) to exclude previously reported polymorphisms. The potential functional impact of a missense mutation was assessed computationally based on inter-species homology and/or structural features of the involved aminoacid residue through the algorithms SIFT 10 In the OCI-AML2 cell line, a homozygous/hemizygous C to T transition was detected at genomic position 98660 (that is, in the 16th exon represented in the transcript), coding for a R635W amino-acid substitution in the methyltransferase domain of the DNMT3A protein ( Figure 1 , top and bottom panels).
In the OCI-AML3 cell line, a heterozygous C to T transition was detected at genomic position 108217 (that is, in the 23rd exon represented in the transcript), coding for a R882C aminoacid substitution also in the methyltransferase domain of the DNMT3A protein ( Figure 1 , middle and bottom panels). Conversely, the U937, KG1 and HL-60 cell lines did not harbor coding mutations in any exons of DNMT3A.
The OCI AML2 cell line 12 carries various cytogenetic abnormalities (for details, see the German Collection of Microorganisms and Cell Cultures, DSMZ, Braunschweig, code ACC 99), but no coding mutations have been so far annotated for OCI-AML2 in the COSMIC database (Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK) in any of the 64 cancer genes analyzed so far (http://www.sanger.ac.uk/perl/genetics/ CGP/core_line_viewer?action ¼ sample&id ¼ 910947, accessed on April 2011), including AML oncogenes such as NPM1, FLT3, IDH1, KIT, RAS and TET2. Therefore, our results represent the first report of a mutation present in OCI-AML2 that affects a geneFDNMT3AFfrequently mutated in AML-NK. Interestingly, this mutation (R635W), although not previously described in AML patients, 5, 6 has been reported in 1/12 DNMT3A-mutated patients among 150 with myelodysplastic syndromes analyzed. 13 The involved amino-acid residue is located in the Letters to the Editor methyltransferase domain of DNMT3A, similar to most of the DNMT3A mutants reported so far in AML. 5, 6 Indeed, computational predictions based on conservation across species and/or physical properties of the affected amino-acid residue indicate that replacement of arginine (a positively charged amino acid) with tryptophan (an aromatic amino acid) at position 635 is likely to have a functional consequence according to both algorithms tested (Wang et al. 12 and our results; SIFT score: 0, indicating protein function likely affected with the strongest possible score; PolyPhen-2 score: 1, indicating a probably damaging mutation with the strongest possible score). Homozygous/hemizygous mutations in DNMT3A, such as that occurring in OCI-AML2, are very rare in DNMT3A-mutated AML or MDS patients who usually show heterozygosity with mRNA expression of the wild-type DNMT3A allele, including the MDS patient with the R635W DNMT3A mutation. 13 However, 1 out of the 23 DNMT3A-mutated AML cases reported by Yan et al. 6 carried a homozygous/hemizygous mutation characterized by the exclusive expression of the G453C-encoding mutant allele.
We previously identified the OCI-AML3 (ref.12) as the only AML cell line carrying an NPM1 mutation (type A) and the immunocytological hallmark of NPM1-mutated AML, that is, the aberrant cytoplasmic dislocation of nucleophosmin.
14 Here, we report for the first time that OCI-AML3 also harbors a DNMT3A mutation of the R882C type, affecting the codon most commonly involved in patients with DNMT3A-mutated AML. 5, 6 Notably, this finding is in line with the observation that AML patients with NPM1 mutations frequently (55-58% of cases) harbor DNMT3A mutations also. 5, 6 The close association between DNMT3A and NPM1 mutations in AML-NK is interesting, but yet poorly understood. NPM1 mutations define a provisional entity in the 2008-WHO classification, and exhibit features of a driver initiating genetic lesion in AML. 3 Because of their wide distribution among AML-NK without association with specific gene expression or methylation profiles, 5 DNMT3A mutations seem to represent a secondary event related to tumor progression. Hypothetically, DNMT3A and NPM1 could cooperate by interfering with epigenetic regulatory mechanisms. In fact, the multiple functions of NPM1 also include control of chromatin structural remodelling. NPM1 proteins are involved in binding to histones H3, H4, H2A and H2B through the NPM1 core region and acid stretches (A1, A2 and A3). 15 Moreover, acetylation of NPM1 causes nucleosome disruption and transcriptional activation. 16 By interacting with histones, NPM1 may participate in chromatin remodelling, thus affecting assembly/disassembly of nucleosomes and regulating DNA-dependent activities, such as transcription, replication and repair. Interestingly, AML with mutated NPM1 exhibits distinct epigenetic profiles, 8 and drugs that act on epigenetic mechanisms, such as the DNA methyltransferase inhibitor 5-azacytidine , were reported to be active on minimal residual disease of a patient with NPM1-mutated AML. 17 In conclusion, the identification of two human AML cell lines, OCI-AML2 and OCI-AML3, harboring DNMT3A mutations alone or in association with NPM1 mutations, respectively, represents an important finding, which should help to better clarify the role of DNMT3A in leukemogenesis, to investigate how DNMT3A and NPM1 mutations cooperate with each other, and to correlate drug response with DNMT3A mutational status in different AML genetic backgrounds (NPM1 wild-type or mutated).
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Letters to the Editor
The surface molecule signature of primary human acute myeloid leukemia (AML) cells is highly associated with NPM1 mutation status Even though human acute myeloid leukemia (AML) is characterized by an expansion of malignant myeloblasts, these immature leukemic cells can show signs of differentiation both by morphological examination and by flow-cytometric analysis of membrane molecules. 1 Analysis of this molecular profile is mainly used as a diagnostic tool to detect panmyeloid or lineage-associated differentiation markers, and thereby distinguish between myeloblasts and lymphoid blasts. 2 On the other hand, cytogenetic and molecular genetic analyses are mainly used for prognostic classification of patients. The most important mutations are then FLT3-ITD, which has an adverse prognostic impact, and NPM-1 mutations, which can be associated with a favorable prognosis. 2 Certain cytogenetic and molecular genetic abnormalities are associated with signs of AML cell differentiation, including NPM-1 mutations, which are associated with monocytic morphology and low expression of the CD34 stem cell marker. 3 These last observations suggest that the cell of origin of the NPM-1 mutation is a myeloid progenitor and not the most immature stem cells. In this context we have therefore investigated in more detail the associations between NPM-1 mutations and AML cell differentiation as defined by a limited number of well-characterized surface membrane molecules.
The membrane molecule profile was investigated by flow cytometry for 184 consecutive AML patients. All patients were examined with regard to the expression of CD11c (expressed on monocytes), CD13 (monocytes, neutrophils), CD14 (mainly expressed on monocytes, at lower levels on neutrophils), CD15 (mainly neutrophils, also monocytes), CD33 (appears on myelomonocytic precursors after CD34), CD34 (immature hematopoietic cells), CD45 (leukocytes) and HLA-DR. 4 The French-American-British (FAB) classification was used for morphological evaluation of the differentiation status, 5 and analysis for FLT3 and NPM-1 mutations was performed as previously described. 6 Bioinformatical analyses were performed using the J-Express 2009 analysis suite (MolMine AS, Bergen, Norway) 7 and hierarchical clustering was performed with Pearson's correlation as distance measure and complete weighted linkage. Based on the surface expression level of this limited number of differentiation markers, the patients could be classified by hierarchical clustering into distinct subsets (Figure 1 ). The patients were classified into two major clusters, the most important difference between these two subsets being a low CD34 expression in Cluster I and a high expression in Cluster II.
